Diclofenac Gel from Glenmark Pharmaceuticals Receives FDA Approval

by Madhumathi Palaniappan on  September 15, 2016 at 12:41 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Diclofenac Sodium gel for skin lesion treatment from Glenmark Pharmaceuticals has recently been approved by the United States Food and Drug Administration.
Diclofenac Gel from Glenmark Pharmaceuticals Receives FDA Approval
Diclofenac Gel from Glenmark Pharmaceuticals Receives FDA Approval

"Glenmark Pharmaceuticals Inc USA has been granted final approval by the USFDA for Diclofenac Sodium gel, 3 per cent, the generic version of Solaraze gel, 3 per cent," the company said in a BSE filing.

"According to IMS Health sales data for the 12-month period ending July 2016, the Solaraze Gel, 3 per cent market achieved annual sales of approximately $297.9 million," it said.

Glenmark's current portfolio consists of 110 products authorised for distribution in the US marketplace and 61 Abbreviated New Drug Applications (ANDAs) are pending for approval with the USFDA.

Source: IANS

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive